v3.25.2
Intangible Assets and Consideration Payable (Details) - USD ($)
3 Months Ended 6 Months Ended
Apr. 30, 2025
Mar. 21, 2025
Feb. 02, 2025
Jan. 16, 2025
Nov. 01, 2024
Aug. 01, 2024
May 03, 2024
Jan. 15, 2024
Jun. 30, 2025
Jun. 30, 2025
Jun. 30, 2024
Mar. 15, 2025
Feb. 27, 2025
Dec. 31, 2024
Intangible Assets and Consideration Payable [Line Items]                            
Purchase price                   $ 6,000 $ 112,320      
Cost of intangible assets                 $ 2,072,632 2,072,632       $ 2,884,549
Termination intangible asset                   129,613        
Shares issued (in Shares)   12,000                        
Shares value   $ 6,000             1,467,582 1,467,582        
Legal fees                   $ 12,320        
Shares were fully vested (in Shares)     438 180 437 437 438     1,750        
License [Member]                            
Intangible Assets and Consideration Payable [Line Items]                            
Intangible assets license term               10 years            
Purchase price               $ 1,000,000            
Intangible asset payable               50,000       $ 350,000    
Undiscounted obligation payable                         $ 950,000  
Cost of intangible assets                       861,452
Percentage of market interest rate                   11.75%        
Technology [Member]                            
Intangible Assets and Consideration Payable [Line Items]                            
Intangible asset payable               $ 600,000            
License #2 (IPR&D asset) [Member]                            
Intangible Assets and Consideration Payable [Line Items]                            
Cost of intangible assets                 2,072,632 $ 2,072,632       $ 2,023,097
Pharmaceutical Company [Member]                            
Intangible Assets and Consideration Payable [Line Items]                            
Fair value adjustment                   15,624        
Pharmaceutical Company [Member] | License [Member]                            
Intangible Assets and Consideration Payable [Line Items]                            
Cost of intangible assets                 861,452 861,452        
Pharmaceutical Company [Member] | License #2 (IPR&D asset) [Member]                            
Intangible Assets and Consideration Payable [Line Items]                            
Cost of intangible assets                 $ 2,023,097 2,023,097        
Common Stock [Member]                            
Intangible Assets and Consideration Payable [Line Items]                            
Consideration paid                   $ 400,000        
Shares issued (in Shares)                 593,194 593,194        
Shares value             $ 59 $ 59        
Fair value adjustment                   $ 173,100        
Shares were fully vested (in Shares)                   437        
Common Stock [Member] | Pharmaceutical Company [Member]                            
Intangible Assets and Consideration Payable [Line Items]                            
Shares issued (in Shares)                   679        
Shares value                   $ 492,850        
Fair value adjustment                   599,863        
Acquiring license                   $ 1,117,771